References
Wald NJ, Law MR. A strategy to reduce cardiovascular disease by more than 80%. Br Med J. 2003;326(7404):1419–23.
Roshandel G, Khoshnia M, Poustchi H, et al. Effectiveness of polypill for primary and secondary prevention of cardiovascular diseases (PolyIran): a pragmatic, cluster-randomised trial. Lancet [Internet] 2019;394(10199):672–83. Available from: https://doi.org/10.1016/S0140-6736(19)31791-X
Yusuf S, Joseph P, Dans A, et al. Polypill with or without Aspirin in Persons without Cardiovascular Disease. N Engl J Med. 2021;384(3):216–28.
Huffman MD, Patel A. Polypills — A Central Strategy for Improving Cardiovascular Health. N Engl J Med [Internet] 2021;384(3):288–9. Available from: https://doi.org/10.1056/NEJMe2033310
Ramos F. “Polypill” to fight cardiovascular disease: birthday present was much appreciated. BMJ [Internet] 2003;327(7418):808; discussion 809; author reply 809–10. Available from: http://europepmc.org/abstract/MED/14525892
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Conflict of interest
The authors declare no conflict of interest.
Additional information
Publisher's note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Khalili, D., Hadaegh, F., Pirzadeh, M. et al. Polypill's cardiovascular and non-cardiovascular mortalities. J Diabetes Metab Disord 20, 2133–2134 (2021). https://doi.org/10.1007/s40200-021-00885-1
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40200-021-00885-1